Pharmaceutical company focusing on identifying and developing clinical-stage compounds for orphan diseases and diseases with unmet medical needs Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announced having appointed Dr. Dennis Langer M.D, J.D as a senior advisor to the company.
Dr. Langer is now responsible for advising the company on strategic matters related to Tryp’s drug development programs for eating disorders, chronic pains and also giving provisional insights to the company’s investors.
Dr. Langer possess huge experience when it comes to the medical sector, he has served as a director, chief executive officer and co-founder of a number of public and private biotechnology, diagnostic and pharmaceutical companies.
He has been the senior vice president of research and development at GlaxoSmithKline, he has also served as the chief executive officer of Neose Technologies.
Currently, Dr. Langer is serving as the director of Myriad Genetics Inc. and the Whitehead Institute for Biomedical Research.
“I am looking forward to advising Tryp Therapeutics as they near the initiation of Phase 2a clinical trials this year. The Company continues to execute on its milestones and is unique in their strategy to deliver psilocybin-based solutions to chronic pain and other indications with critically unmet needs. The ultimate commercial potential for Tryp’s products is significant,” said Dr. Langer.
